OGGIONI, NORBERTO
 Distribuzione geografica
Continente #
NA - Nord America 8.473
EU - Europa 4.222
AS - Asia 1.510
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 21
AF - Africa 13
SA - Sud America 13
Totale 14.276
Nazione #
US - Stati Uniti d'America 8.299
DE - Germania 894
SE - Svezia 841
CN - Cina 812
IE - Irlanda 667
IT - Italia 543
UA - Ucraina 526
GB - Regno Unito 253
HK - Hong Kong 210
CA - Canada 170
VN - Vietnam 131
FI - Finlandia 114
AT - Austria 99
SG - Singapore 91
RU - Federazione Russa 76
IN - India 69
DK - Danimarca 63
FR - Francia 63
KR - Corea 54
ID - Indonesia 40
JP - Giappone 32
TR - Turchia 26
NL - Olanda 25
MY - Malesia 21
EU - Europa 18
BE - Belgio 17
NZ - Nuova Zelanda 17
IR - Iran 15
PL - Polonia 12
BR - Brasile 8
EG - Egitto 8
AU - Australia 7
ES - Italia 7
BG - Bulgaria 4
CL - Cile 4
CZ - Repubblica Ceca 4
HR - Croazia 4
HU - Ungheria 4
MX - Messico 4
AE - Emirati Arabi Uniti 3
RS - Serbia 3
A1 - Anonimo 2
LB - Libano 2
NG - Nigeria 2
PT - Portogallo 2
SA - Arabia Saudita 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
KW - Kuwait 1
MA - Marocco 1
TW - Taiwan 1
VE - Venezuela 1
Totale 14.276
Città #
Ann Arbor 1.879
Woodbridge 819
Chandler 706
Dublin 651
Jacksonville 543
Houston 523
Fairfield 455
Wilmington 446
Frankfurt am Main 430
Dearborn 424
Ashburn 316
New York 266
Princeton 244
Milan 229
Hong Kong 193
Seattle 174
Nanjing 172
Boardman 169
Cambridge 136
Shanghai 102
Vienna 99
Lachine 89
Dong Ket 78
Altamura 73
Lawrence 71
Beijing 64
Nanchang 59
Guangzhou 58
Andover 42
Fremont 42
Singapore 42
Grafing 40
Jakarta 40
Shenyang 40
Jinan 35
Toronto 35
Jiaxing 34
Nürnberg 33
San Diego 30
Falls Church 26
Ottawa 25
Tianjin 25
Daejeon 24
Kunming 23
Mountain View 23
Hangzhou 22
Hebei 22
Helsinki 22
Pune 22
Zhengzhou 22
Changsha 21
Los Angeles 21
Sacramento 19
Brussels 17
Leawood 16
Chicago 14
Ningbo 14
Edmonton 13
Huizen 13
Bergamo 12
Norwalk 12
Pasir Mas 12
Regensburg 12
Shinjuku 12
Phoenix 11
Rome 11
Taizhou 11
Auburn Hills 10
Hefei 10
Kiev 9
San Mateo 9
Yongin-si 9
Carate Brianza 8
Codroipo 8
London 8
Philadelphia 8
Changchun 6
Detroit 6
Lissone 6
Mainz 6
Washington 6
Wuhan 6
Ankara 5
Auckland 5
Cagliari 5
Clarks Summit 5
Frederick 5
Haikou 5
Laurel 5
Redmond 5
Secaucus 5
Seoul 5
Suwon 5
Tappahannock 5
Tokyo 5
Fuzhou 4
Induno Olona 4
Kocaeli 4
Lanzhou 4
Man Kok 4
Totale 10.578
Nome #
Age-related changes in the function and structure of the peripheral sensory pathway in mice 286
Global transcriptomic profile of dorsal root ganglion and physiological correlates of cisplatin-induced peripheral neuropathy 279
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 274
Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells 258
Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy 257
Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models 223
Neuropathic pain is reduced in acid sphingomyelinase deficient mice. 221
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 207
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 191
Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study 189
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 189
Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity 186
Bortezomid-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. 180
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 178
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 174
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats 172
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats 171
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse 170
Effects of Islet Transplantation and Mesenchymal Stem Cell Co-Transplantation in the Protection of Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats 170
The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity 168
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 167
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 163
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth 162
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 161
Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model 158
Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE 156
Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor 155
Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies 155
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity 154
In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™) 152
Toward the identification of neuroprotective agents: G-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist 151
Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats 150
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies 148
Platinum-taxane combination chemotherapy: General and peripheral neurotoxicity of their combined administration in the rat 144
Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration 144
Lipoplatin tm: a less neurotoxic formulation of cisplatin 144
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 144
Bortezomib-Induced Peripheral Neurotoxicity: a Preclinical Model to Study Neuropathic Pain in Rat 143
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity 142
Islet transplantation and insulin administration relieve long-term complications and rescue the residual endogenous pancreatic β cells 142
Platinum-Taxane combination chemotherapy: assessment of electrophysiologic pathologic and morphometric fetures in chronic wistar rat models 141
Bortezomib-induced peripheral neurotoxicity: A neurophysiological study in a rat model 139
Cr4056: a novel potent anti-nociceptive agent for several animal models of neuropathic pain 139
Granulocytes in actively induced Lewis rat EAE 138
Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats 137
Erythropoietin both protects from and reverses experimental diabetic neuropathy 136
Reply to a comment paper on the published paper by canta, a. Et al: “calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity”—antioxidants 2020, 9, 594 135
Platinum-taxane combination chemotherapy: Description of the first study to assess the general and peripheral neurotoxicity of their combined administration in the rat 134
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis 134
Actively induced EAE in Lewis rats: Characterization of spleen and spinal cord infiltrating lymphocytes by flow cytometry during the course of the disease 132
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 131
Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis 129
Valproate protective effects on cisplatin-induced peripheral neuropathy: An in vitro and in vivo study 128
Immunomodulating effects of extracorporeal photochemotherapy in rat experimental allergic encephalomyelitis 128
Regression of diabetic complications by islet transplantation in the rat 126
The role of the complete Freund’s adjuvant and neutrophils in actively induced Lewis rat EAE 126
Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system 123
Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy 122
Multimodal experimental approach to the study of human neurological diseases 120
Antibody Against Tumor Necrosis Factor-α Reduces Bortezomib-induced Allodynia in a Rat Model 119
BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY: STUDY OF PROTEASOME INHIBITION AND MICROTUBULE STABILIZATION MECHANISMS IN RAT MODEL 117
A Possible role of OCT2 gene in the development of peripheral neurotoxicity induced by cisplatin 117
Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice 116
Organic cation transporter 2 mRNA expression in dorsal root ganglia neurons 116
Effect of preventive and therapeutic treatment of ghrelin agonist HM01 on the peripheral neurotoxicity induced by bortezomib in wistar rats. 115
ANALGELSIC EFFECT OF BUPRENORPHINE IN AN EXPERIMENTAL MODEL OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY 114
Characterization of spleen and spinal cord infiltrating lymphocytes during actively induced EAE in Lewis rats. 112
Ethoxyquin is effective in preventing cisplatin-induced painful peripheral neuropathy in rats 111
Morphometrical characterization of DRG alterations induced by cisplatin and bortezomib in several mice models 110
Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis 109
Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy 109
Pain-related behaviour and analgesic effect of gabapentin in an experimental model of bortezomib-induced neuropathic pain 109
Effect of proteasome inhibition on the central and peripheral nervous system 108
CISPLATIN, EPOTHILONE B AND BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHIES: A NEUROPHYSIOLOGICAL STUDY IN THE MOUSE. 107
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 107
Preventive treatment with anti-rat neutrophil serum affects the relapsing phase in Dark Agouti EAE rats 104
Characterization of Glutamate Transporters in Peripheral Nervous System. 104
Oxaliplatin-Induced Peripheral Neurotoxicity: Morphological Characterization In Different Mouse Strains 104
The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats 103
Bortezomib-induced neuropathic pain: evaluation of antinociceptive effect of a new analgesic compound 102
Effect of different chronic treatment modalities on the peripheral neurotoxicity of sagopilone in rats: a multimodal analysis 98
Macrophage infiltration in different preclinical models of chemotherapy-induced peripheral neurotoxicity 98
Functional recovery with syngeneically transplanted microcapsulated pancreatic islets in streptozotocin-induced diabetic rats. 96
EXPRESSION OF TRPV1 AND CGRP IN SPINAL PRIMARY AFFERENT NEURONS IN A RAT MODEL OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY TREATED WITH ANALGESICS 94
Neutrophil contribution and immunoglobulin effect in Dark Agouti Experimental Autoimmune Encephalomyelitis. 93
Neurotoxicity ad neuropathic pain induced by Bortezomib: evaluation of peripheral nerve fibres from a clinical to an ultrastructural level. 90
Characterization of the neurotoxicity and antineoplastic activity of bortezomib in a new myeloma-bearing murine model. 90
Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain 89
STANDARD AND ADVANCED NEUROPHYSIOLOGY SET UP IN MOUSE MODELS: SENSORY RECORDINGS AND NERVE EXCITABILITY TESTING OF THE CAUDAL NERVE. 88
Evaluation of the neuroprotective effect of acetyl-l-carnitine in myeloma-bearing mice treated with bortezomib 87
Effects of palmitoylethanolamide (pea) in cisplatin-induced peripheral neuropathy in mice. 87
CHARACTERIZATION OF PERIPHERAL NEUROPATHY INDUCED BY CHRONIC CISPLATIN ADMINISTRATION IN SEVERAL MICE MODELS 84
Biodistrubution and toxicology of two PFCs intravenously injected in rats 84
Neurotoxicity and neuropatic pain induced by Bortezomib:evaluation of peripheral nerve fibres from a clinical to an ultrastructural level 81
STUDY OF THE CALCITONIN GENE-RELATED PEPTIDE-POSITIVE INTRAEPIDERMAL NERVE FIBERS IN A RAT MODEL OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY 81
The new analgesic CR4056 effectively abrogates neuropathic pain induced by Bortezomib in rats 79
An innovative traslational approach to oxaliplatin induced peripheral neurotoxicity in animal models: nerve excitability testing. 79
The part of the Complete Freund’s Adjuvant in actively induced Experimental Autoimmune Encephalomyelitis in Lewis rat. 79
L-serine supplementation suppresses the formation of neurotoxic deoxysphingolipids and improves neuropathy in a type 1 diabetic rat model 77
Topiramate neuroprotectant effects against oxaliplatin induced peripheral neurotoxicity 77
Totale 13.720
Categoria #
all - tutte 42.426
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.426


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019297 0 0 0 0 0 0 0 0 0 0 0 297
2019/20202.958 369 186 210 184 261 366 486 186 265 212 199 34
2020/20212.346 128 76 259 252 205 197 265 197 205 194 132 236
2021/20221.395 81 139 137 127 96 142 65 76 57 116 102 257
2022/20232.668 297 735 235 260 199 431 34 139 214 30 52 42
2023/20241.935 65 62 79 67 274 536 351 89 101 40 23 248
Totale 15.164